Transmission of human papillomavirus in heterosexual couples.
Cervical cancer remains a major source of illness and death among women globally, and infection with oncogenic human papillomaviruses (HPVs) is its principal cause (1,2). Men are assumed to be the main reservoirs of genital HPV infection for women, although comparatively little is known about the natural history of HPV in men.
A limited number of cross-sectional and case-control studies have evaluated genotype-specific HPV concordance in male-female couples (3-7). There are, however, no empirical data on the heterosexual transmission of HPV. Our investigation evaluates the transmission of HPV in a cohort of male-female sexual partners.
The study was conducted at the University Health Services of the University of Hawaii at Manoa from February 2005 through November 2006. Promotional efforts includ ed flyers and email invitations, which were part of larger ongoing studies of HPV. The study was approved by the Committee on Human Studies of the University of Hawaii. All study participants provided written informed consent. Eligible participants were at least 18 years of age, English-speaking, not currently pregnant, and in a monogamous relationship with the index partner.
Couples attended concurrent study visits at 2-month intervals. Trained clinicians collected exfoliated cell samples for HPV DNA detection. For men, separate genital specimens from the penis glans/corona, penis shaft, scrotum, and inner foreskin (uncircumcised men) were collected by using textured paper and a saline-moistened swab (8,9). Anal canal specimens were collected by using a saline-moistened swab. A cytobrush was used to collect oral specimens (buccal cavity, tongue). Specimens from the dominant hand (palm, fingertips, under the fingernails) were collected by using a saline-moistened swab. Participants self-collected first-catch urine samples (30 mL) at the clinic. Using latex gloves, men collected semen specimens at home during masturbation within 24 hours of each visit.
For women, a cervical cytology (Papanicolaou [Pap]) smear was collected, and a swab and cytobrush were used to consecutively sample the ectocervix and endocervix, including the transformation zone. The same methods used for collection of anal, oral, hand, and urine specimens from men were used for collection of specimens from women.
HPV DNA Testing and Genotyping
DNA was extracted from specimens by using commercial reagents (QIAGEN, Valencia, CA, USA). The PCR used PGMY09/PGMY 11 primers to amplify a 450-bp region of the L1 HPV genome (10). Amplification of the human [beta]-globin gene was included as an internal control for sample sufficiency. HPV-positive specimens were subsequently genotyped by using commercial reagents (Roche Molecular Systems Inc., Branchburg, N J, USA) originating from a prototype line blot assay (11). The assay detects 37 different HPV types, including oncogenic/probable oncogenic types (HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82, and IS39, a subtype of HPV 82), nononcogenic types (HPV 6, 11, 40, 42, 54, 61, 70, 72, 81, and CP6108, also known as candidate HPV 89), and types with undetermined risk status (HPV 55, 62, 64, 67, 69, 71, 83, and 84) (12,13). This PCR-based assay has demonstrated a high degree of sensitivity and reproducibility (14-16). HPV testing and genotyping procedures have been given in detail previously (9).
The main objective of the statistical analysis was to evaluate HPV transmission between partners. Each type-specific HPV infection was assigned a status of transmitted or not transmitted by time period and anatomic site. For some statistics, the penis anatomic site was further divided into foreskin, glans, shaft, and urine, which is a proxy for urethral infection. HPV in female urine, which has demonstrated type-specific concordance with cervical measurements (17), was considered to be a proxy for cervical and other lower genital tract infections. Therefore, cervix and urine were combined as 1 anatomic site. When there were >1 possible source sites, sites were grouped and evaluated as 1 transmission event. When there were >2 destination sites, each was counted as a separate transmission event.
Partner transmission was defined as the presence of a specific HPV genotype at an anatomic site in 1 partner and its absence in all sites of the other partner at a given visit, along with the presence of this HPV type in the unaffected partner at the subsequent visit. Auto-inoculation was defined as the presence of a particular HPV type at an anatomic site in 1 partner and its absence in all sites of the other partner at a given visit, and the presence of this HPV type in a different anatomic site in the affected partner at the subsequent visit. An event was defined as self-inoculation only after possible transmission from the partner was ruled out, i.e., when the partner was negative for the HPV genotype at prior and concurrent visits.
The rate of HPV transmission was calculated as the number of HPV type-specific transmission events divided by the number of person-months of exposure x 100 and expressed as the rate per 100 person-months. Exact confidence intervals (CIs) for transmission rates were calculated by assuming a Poisson distribution for the number of events (18). Person-months of exposure for each HPV infection by anatomic site were computed based on the period of time between successive visits. When HPV was detected at a given visit and HPV type was absent at the successive visit, the exposure period was estimated at half of the visit interval. Comparisons between couples by transmission status were made by using the t test, [chi square] statistic, and linear rank statistic.
Thirty-eight couples (38 men, 38 women) were enrolled. Six couples left the study, including 2 whose relationships ended. The present analysis focuses on 25 couples with at least 2 visits. Couples were followed up at [approximately equal to]2-month intervals over an average of 7.5 months.
The mean age was 28 years (range 18-59 years) for men and 26 years (range 18 57 years) for women. Participants comprised Caucasians (52%), Asians (8%), Pacific Islanders (6%), and persons of other single- or mixed-race backgrounds (34%). Couples were single/never married (48%), living together as married (32%), separated/divorced/widowed (12%), and married (8%). All participants indicated that the index partner was their only current sexual partner, and all reported vaginal intercourse with penile penetration during the follow-up period.
Five men were uncircumcised. At study entry, 1 woman had cervical low-grade squamous intraepithelial lesions, and 2 men had genital warts. Cervical atypia was diagnosed in 2 women during follow-up.
Overall, 957 (94%) of 1,015 specimens were adequate based on [beta]-globin detection and were included in the present analyses. At study entry, 7 couples were HPV negative at all anatomic sites, 4 couples had 1 HPV-positive partner (3 were anal infections in the man), and 14 couples had both partners HPV positive. Of the 14 couples positive for HPV, 3 couples were positive for different HPV types, and 11 were positive for the same HPV type(s) at 1 or more anatomic sites (Table 1). All 11 HPV type-specific concordant infections involved the penis in the male partner and, with 2 exceptions, the cervix and/or urine in the female partner.
All transmission events occurred in couples with 1 or both partners positive for HPV at study entry. A total of 78 transmission events were observed in 16 couples, including 14 male-to-female, 39 female-to-male, 21 male auto-inoculation, and 4 female self-inoculation (online Appendix Table, available from www.cdc.gov/content/14/6/888-appT. htm). Overall, 15 different genotypes were transmitted, including oncogenic types and nononcogenic/undetermined risk types. Partner transmission involved 13 genotypes. Forty-one (53%) of the 78 transmission events involved multiple potential sources of infection.
Male-to-female transmission was observed in 7 couples. All infections transmitted from male to female partners originated in the penis with or without additional involvement of the scrotum. In particular, the penis shaft was a predominant source of infection either alone or with other genital sites. The cervix and anus were the most frequent targets of transmission from the men. Transmission of oncogenic HPV 16 comprised 1 of the 5 genital-to-cervix events. Male genital to female hand transmission was observed in 3 couples (D, E, and G).
Female-to-male transmission was observed in 12 couples. Transmission from the cervix and/or urine to the male genitals comprised most female-to-male events. Within penis subsites, the glans was targeted more frequently than the shaft. The anus was frequently an additional source site along with the cervix/urine. In addition, the anus was the sole source of transmission to the male genitals on 4 occasions, of which 3 targeted the partner's scrotum (couples A, B, and J). The penis and scrotum, respectively, were the most frequent targets of infection from women. There were 4 instances of transmission from the woman's hands to the man's genitals, including 1 case in which it was the sole source (couple I). Oncogenic HPV types 16 and 18 were transmitted in only 2 of the 39 female-to-male events.
Male self-inoculation was observed in 11 men, including 3 for whom no heterosexual transmission was observed during the entire period of follow-up. Sixteen events involved transmission between different genital sites, 2 involved anal-to-genital transmission, and 3 involved genital-to-hand transmission. Most genital-to-genital events involved transmission between penis subsites. In 3 instances, male self-inoculation immediately preceded transmission of HPV to female partners (couples A and B).
Female self-inoculation was observed in 4 females. All involved urine as a source site and 3 of these targeted the hands.
Heterosexual transmission of the same HPV genotype to >1 anatomic site (excluding penis subsites) was observed on 13 occasions. Eight of these cases involved transmission from the cervix/urine to the penis and scrotum.
Heterosexual transmission of multiple genotypes to the same anatomic site during the same period was observed in 5 instances (couples A, B, D, F, and G); the scrotum was the target site on 3 of these occasions. In 1 case, different genotypes in the cervix and urine were each transmitted to both the penis glans and shaft (couple K).
Transmission of some HPV types in preference to others was also observed. In couple L, after cervical infection with HPV 16 and 31 was detected at study entry, only HPV 31 was transmitted to the penis (glans, shaft) and scrotum. Alternatively, the female anus may have been the source of infection because HPV 31, not HPV 16, was present in the anus at baseline. In couple D, HPV 16, 59, and 62 were present in the penis shaft at baseline. Subsequently, only HPV 16 was transmitted to the woman's cervix/urine and anus by the second visit.
A number of instances indicated apparent reinfection after viral clearance. In 1 couple (A), the woman's anus was positive for HPV 39 infection at baseline and at visit 2. By visit 3, HPV 39 had been transmitted to the man's scrotum, and the woman was negative for HPV 39. HPV 39 had been transmitted (presumably by auto-inoculation) to the penis by visit 4, and the infection remained through visit 5. By visit 6, or 9 months after initial clearance in the woman, HPV 39 had been transmitted to the woman's anus.
Four cases of transmission to the female anus required >4 months of exposure to an infected partner. In 27 incident infections, no source of infection could be ascertained; 17 of these infections were in the male genitals.
The rates of HPV transmission by source site are shown in Table 2. Overall, the rate of transmission from the penis to the cervix/urine was 4.9 per 100 person-months of exposure (95% CI 1.6-10.0). By contrast, the overall rate of transmission from the cervix/urine to the penis was 17.4 per 100 person-months of exposure (95% CI 10.6-25.8). Transmission of oncogenic types to the male genitals was greater from the female urine alone than from the cervix alone. Transmission of HPV from the penis to the female anus was higher than that to the cervix; this was particularly true for transmission of oncogenic types to the anus (12.2 per 100 person-months of exposure, 95% CI 3.9-24.9). The highest rates of transmission were observed from the female anus to the male genitals (47.1 per 100 person-months of exposure, 95% CI 30.2-67.7), followed by cervix to the male genitals (27.8 per 100 person-months of exposure, 95% CI 19.0-38.3). In men, the rate of transmission by auto-inoculation was comparable to that of transmission from women. For example, the rate of transmission from the scrotum alone to the penis (6.0 per 100 person-months of exposure, 95% CI 1.2-14.5) was comparable to that of cervix only to penis (5.0 per 100 person-months of exposure, 95% CI 1.0-11.9).
All couples with genital-to-genital transmission reported vaginal intercourse during the period corresponding to the transmission event. Among the 5 couples with penis-to-anus transmission, 4 reported anal intercourse during the corresponding time period.
Table 3 compares baseline characteristics of couples with and without HPV transmission. Male partners in transmitting couples had had more sexual partners over their lifetime. Transmitting couples had more frequent sexual intercourse with one another, were more likely to have contact between the male's mouth and the female's anus, were more likely to use birth control injections and have withdrawal before ejaculation, and had fewer periods of abstinence. Over half of nontransmitting couples reported use of condoms 100% of the time during sexual intercourse within the previous 4 months, compared with only 3% of transmitting couples.
This study demonstrates that HPV is efficiently transmitted between sexual partners and that multiple transmission events can occur within a couple. The rates of genital transmission from women to men were substantially higher than from men to women. Greater rates of female-to-male transmission should imply higher HPV prevalence in men. Studies in men to date, including our own cohort, have reported male genital HPV prevalences at least as high as in women, with most reporting prevalences of at least 20% and up to 73% (9,19). The penis shaft was the primary source of transmission to the cervix; the cervix and urine were the primary sources of infection to male genitals.
Sexual transmission also involved the scrotum, the anus of women, and the hands of both sexes. The oral cavity and semen were not involved in transmission.
The anus of women was both a major source and target of heterosexual transmission. We observed consistency between penis-to-female anus transmission and reported anal intercourse during the corresponding period. We previously demonstrated high genotypic concordance between concurrent cervical-anal infections in women, which indicates possible common sources of infection (20).
Transmission through nonpenetrative sexual contact was demonstrated between the female anus and the scrotum, as well as the female hand and male genitals. The male anus was not a major source or a target of HPV transmission. However, 3 of the 4 couples with baseline infection in only 1 partner involved anal infection in men.
Male self-transmission frequently involved the scrotum, likely facilitated by passive contact between proximate genital sites. The scrotum may be an important reservoir of infection for penile infections that can subsequently be transmitted to partners. Hands may also serve as reservoirs of infection in both men and women. Auto-inoculation involving the hands may result from casual contact or masturbation.
To some extent, our study results suggest that HPV is relatively indiscriminate in its patterns of transmission. We observed the transmission of a given viral genotype to multiple anatomic sites in a partner and concurrent transmission of multiple genotypes to the same site.
Other observations suggest that HPV transmission is not entirely arbitrary and may reflect tissue or genotype differences or both. Rates of transmission of oncogenic types to the male genitals from the urine were higher than from the cervix. This may reflect differences in genotypes found in the vagina and vulva compared with those found in the cervix. All transmission events requiring extended periods of exposure involved the female anus target site.
A total of 15 genotypes were transmitted, including 13 which were transmitted through heterosexual means. HPV 16 and 18 and nononcogenic HPV 6 and 11, the 4 types included in the current quadrivalent vaccine, comprised <10% of transmitted types. Notably, we observed greater transmission of HPV 16 to the cervix than such transmission by other types, which underscores the possibility of selective transmission of some HPV types.
Compared with couples not experiencing HPV transmission, transmitting couples were more sexually active and were more likely to use certain nonbarrier forms of contraception. Few HPV-transmitting couples reported always using condoms during recent sexual activity, compared with over half of nontransmitting couples.
A major limitation of our study was the potential for misclassification of HPV transmission events. Variable detection of HPV could be due to natural fluctuation in viral levels or variable sampling of sites could confound the observation of viral transmission. For example, instances of apparent reinfection of sites may alternatively represent possible reactivation of latent infections.
Another potential source of misclassification was the lack of a priori knowledge of the time required for HPV to be acquired from an infected partner. Viral transmission could have occurred more frequently than the 2-month visit intervals used in the study, and transmission events could have been missed.
Another limitation of the study was the inclusion of couples who had already had sexual contact with one another; initial viral transmission was likely to have occurred before study entry. Indeed, nearly half of the couples had type-specific concordant infections at study entry, indicating previous transmission of HPV, which limited our ability to evaluate incident infections.
Because our study relied on self-reported sexual activity, it was subject to recall bias. Furthermore, although all persons reported monogamous relationships, some of the incident infections without a source, most of which involved the male genitals, could have been acquired through sexual activity with another partner. Despite these limitations, the present study included intensive follow-up of a well-characterized cohort, sampling of multiple genital and nongenital sites, and state-of-the-art HPV testing and genotyping methods.
The development of comprehensive HPV prevention and control strategies, which incorporate HPV vaccine usage and contraceptive practices, is impeded by lack of information on the risk and routes of sexual transmission between heterosexual partners and potential genotype-specific differences in transmission efficiency. The small size of the cohort and the diversity of genotypes precluded type-specific analysis of transmission.
This study contributes to a growing body of knowledge of HPV in men because we directly examined HPV transmission. However, study results are preliminary and need to be verified in larger cohorts. Future HPV transmission studies are critical to address major gaps in our knowledge of the natural history of this virus.
We extend our gratitude to the staff of the University of Hawaii, Cancer Research Center of Hawaii, and the University of Hawaii University Health Services whose clinical staff conducted specimen collection for the study.
This project was supported in part by the Centers of Biomedical Research Excellence Program award P20 RR018727 from the National Center for Research Resources, and National Cancer Institute grant R01 CA077813.
Dr Hernandez is an epidemiologist at the Cancer Research Center of Hawaii, University of Hawaii. Her research focuses on the molecular epidemiology of cancer including the role of infectious agents in the development and progression of cancer. She has investigated the epidemiology of HPV in both women and men.
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits [TM]. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content: (3) take the post-test and/or complete the evaluation at http://www.medscape,com/cme/eid; (4) view/print certificate.
Upon completion of this activity, participants will be able to:
* Identify the most common baseline human papillomavirus (HPV) status of couples
* Specify the most common mode of transmission of HPV between couples
* Describe the role of anatomic sites in the transmission of HPV
* Identify behavioral factors associated with the transmission of HPV
D. Peter Drotman. MD. Editor-in-Chief. Emerging Infectious Diseases. Disclosure: D. Peter Drotman, MD, has disclosed no relevant financial relationships.
Charles P. Vega. MD. Associate Professor: Residency Director, Department of Family Medicine, University of California, Irvine, California, USA. Disclosure: Charles P Vega, MD. has disclosed that he has served as an advisor or consultant to Novartis, Inc.
Disclosures: Brenda Y. Hernandez, PhD, MPH: Lynne R. Wilkens, DrPH; Xuemei Zhu, MD; Pamela Thompson, MPH; Katharine McDuffie, BS: Yurii B. Shvetsov. PhD: Jeffrey Killeen. MD; Lily Ning, MD: and Marc T. Goodman, PhD, MPH, have disclosed no relevant financial relationships Lori E. Kamemoto, MD, MPH, has disclosed that she has received grants for clinical research from GlaxoSmithKline. and is on the speakers' bureau for Merck.
Article Title Transmission of Human Papillonmavirus in Heterosexual Couples
1. Which of the following was the most common human papillomavirus (HPV) status at baseline in the current study cohort?
A. Both partners HPV-negative
B. One partner HPV-negative and one HPV-positive
C. Both partners HPV-positive with the same HPV type
D. Both partners HPV-positive with different HPV types
2. What was the most common means of HPV transmission in the current study?
A. Male-to-female transmission
B. Female-to-male transmission
C. Male auto-inoculation
D. Female auto-inoculation
3. Which of the following statements about anatomic sites of transmission of HPV in the current study is most accurate?
A. Most women obtained infection from the glans of the penis
B. The female anus was not a significant site of transmission to men
C. There were no cases of transmission from the women's hands to the men's genitals
D. Among men, the rate of auto-inoculation was comparable to the rate of transmission from women
4. Which of the following factors from the current study was most significant in the risk for HPV transmission?
A. Frequency of condom use
B. Length of relationship
C. Any history of anal intercourse
D. A history of genital herpes
(1.) Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1992;84:394-8.
(2.) Bosch FX. de Sanjose S. Chapter 1 : human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
(3.) Ho L, Tay SK, Chan SY, Bernard HU. Sequence variants of human papillomavirus type 16 from couples suggest sexual transmission with low infectivity and polyclonality in genital neoplasia. J Infect Dis.1993;168:803-9.
(4.) Hippelainen MI, Yliskoski M, Syrjanen S, Saastamoinen J, Hippelainen M, Saarikoski S, et al. Low concordance of genital human papillomavirus
(HPV) lesions and viral types in HPV-infected women and their male sexual partners. Sex Transm Dis. 1994;21:76-82.
(5.) Kyo S, Inoue M, Koyama M, Fujita M, Tanizawa O, Hakura A. Detection of high-risk human papillomavirus in the cervix and semen of sex partners. J Infect Dis.1994;170:682-5.
(6.) Strand A, Rylander E, Wilander E, Zehbe I. HPV infection in male partners of women with squamous intraepithelial neoplasia and/or high-risk HPV. Acta Derm Venereol. 1995;75:312-6.
(7.) Baken LA, Koutsky LA, Kuypers J, Kosorok MR, Lee SK, Kiviat NB, et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis. 1995; 171:429-32.
(8.) Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee SK, Meyer C, et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis. 2004;189:677-85.
(9.) Hernandez BY, McDuffie K, Goodman MT, Wilkens LR, Thompson P, Zhu X, et al. Comparison of physician- and self-collected genital specimens for detection of human papillomavirus in men. J Clin Microbiol. 2006;44:513-7.
(10.) Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38:357-61.
(11.) Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36:3020-7.
(12.) de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
(13.) Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24S3: S1-S10.
(14.) Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J Clin Microbiol. 2006;44:1998-2006.
(15.) van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol. 2006;44:3122-9.
(16.) Giuliani L, Coletti A, Syrjanen K, Favalli C, Ciotti M. Comparison of DNA sequencing and Roche linear array in human papillomavirus (HPV) genotyping. Anticancer Res. 2006;26(5B):3939-41.
(17.) Daponte A, Pournaras S, Mademtzis I, Hadjichristodoulou C, Kostopoulou E, Maniatis AN, et al. Evaluation of high-risk human papillomavirus types PCR detection in paired urine and cervical samples of women with abnormal cytology. J Clin Virol. 2006;36:189-93.
(18.) Dobson AJ, Kuulasmaa K, Eberle E, Scherer J. Confidence intervals for weighted sums of Poisson parameters. Stat Med. 1991;10:457-62.
(19.) Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006; 194:1044-57.
(20.) Hernandez BY, McDuffie K, Zhu X, Wilkens LR, Killeen J, Kessel B, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev. 2005; 14:2550-6.
Address for correspondence: Brenda Y. Hernandez, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala St, Honolulu, HI 96813, USA; email: firstname.lastname@example.org
Brenda Y. Hernandez, * Lynne R. Wilkens, * Xuemei Zhu, * Pamela Thompson, * Katharine McDuffie, * Yurii B. Shvetsov, * Lori E. Kamemoto, ([dagger]) Jeffrey Killeen, ([double dagger]) Lily Ning, * and Marc T. Goodman *
* University of Hawaii, Manoa, Hawaii, USA; ([dagger])University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii, USA; and ([double dagger])Kapi'olani Medical Center for Women and Children, Honolulu
Table 1. HPV status of couples at study entry * Man HPV status at baseline No. Site HPV Both partners HPV neg 7 All Neg One partner HPV pos 4 Anus 18 Anus 18 Anus 42/51/52/84 All Neg Both partners HPV pos Different HPV type(s) 3 Anus 6 Shaft 6 Shaft, scrotum 6 One or more of the 11 Shaft 59 same HPV Shaft 59 type(s) ([dagger]) Shaft 84 Shaft 62 Shaft 55 Glans, shaft 56, 59 Shaft, scrotum 62 Foreskin, glans, CP6108 shaft, scrotum Shaft, scrotum 42 Glans, shaft, scrotum 53 Woman HPV status at baseline Site HPV Both partners HPV neg All Neg One partner HPV pos All Neg All Neg All Neg Urine CP6108 Both partners HPV pos Different HPV type(s) Anus 39 Cervix/urine 16 Cervix/urine, anus 31 One or more of the Cervix 59 same HPV Hand 59 type(s) ([dagger]) Cervix 84 Urine 62 Anus 55 Cervix/urine, anus, hand 5,659 Urine, anus, hand 62 Urine, anus CP6108 Cervix/urine, anus 42 Cervix 53 * HPV, human papillomavirus; neg, negative; pos, positive. ([dagger]) Only concordant types shown. Table 2. Rate of HPV transmission by source and target site in male-female coules * No. transmission events Source site Target site Overall Oncogenic Male to female Penis only Cervix/urine 2 1 Penis only Anus 3 3 Penis only Hand 2 1 Any penis Cervix/urine 5 1 Any penis Anus 6 5 Any penis Hand 3 2 Any scrotum Cervix/urine 3 0 Any scrotum Anus 3 2 Any genital Cervix/urine 5 1 Any genital Anus 6 5 Female to male Cervix only Penis 3 0 Cervix only Scrotum 1 0 Cervix only Any genital 4 0 Urine only Penis 2 1 Urine only Scrotum 3 2 Urine only Any genital 5 3 Cervix/urine only Penis 6 2 Cervixurine only Scrotum 5 3 Any cervix/urine Penis 20 12 Any cervix/urine Scrotum 12 8 Any cervix/urine Any genital 32 20 Any cervix/urine Anus 1 1 Any cervix/urine Hands 1 1 Anus only Scrotum 3 1 Any anus Any genital 24 16 Any hands Any oenital 4 2 Self-inoculation Male ([section]) Penis only Scrotum 5 1 Scrotum only Penis 3 2 Any genital Any genital 15 6 Any genital Hands 3 2 Anus only Any genital 3 2 Female Cervix/urine only Anus 1 1 Cervix/urine/anus Hand 3 2 Duration of exposure, mo ([dagger]) Source site Overall Oncogenic Male to female Penis only 102 41 Penis only 102 41 Penis only 102 41 Any penis 102 41 Any penis 102 41 Any penis 102 41 Any scrotum 50 -- Any scrotum 50 27 Any genital 111 51 Any genital 111 51 Female to male Cervix only 61 -- Cervix only 61 -- Cervix only 61 -- Urine only 55 36 Urine only 55 36 Urine only 55 36 Cervix/urine only 115 83 Cervixurine only 115 83 Any cervix/urine 115 83 Any cervix/urine 115 83 Any cervix/urine 115 83 Any cervix/urine 115 83 Any cervix/urine 115 83 Anus only 51 36 Any anus 51 36 Any hands 426 373 Self-inoculation Male ([section]) Penis only 102 41 Scrotum only 50 27 Any genital 111 51 Any genital 111 51 Anus only 29 21 Female Cervix/urine only 115 83 Cervix/urine/anus 166 119 Transmission rate/100 person- months (95% CI) Oncogenic Source site Overall ([double dagger]) Male to female Penis only 1.9 (0.2-5.4) 2.4 (0.06-9.0) Penis only 2.9 (0.6-7.1) 7.3 (1.5-17.6) Penis only 1.9 (0.2-5.4) 2.4 (0.06-9.0) Any penis 4.9 (1.6-10.0) 2.4 (0.06-9.0) Any penis 5.9 (2.2-11.4) 12.2 (3.9-24.9) Any penis 2.9 (0.6-7.1) 4.9 (0.6-13.5) Any scrotum 6.0 (1.2-14.5) -- Any scrotum 6.0 (1.2-14.5) 7.5 (0.9-20.9) Any genital 4.5 (1.5-9.3) 2.0 (0.1-7.2) Any genital 5.4 (2.0-10.6) 9.8 (3.2-20.0) Female to male Cervix only 5.0 (1.0-11.9) -- Cervix only 1.6 (0.04-6.1) -- Cervix only 6.6 (1.8-14.5) -- Urine only 3.7 (0.4-10.2) 2.8 (0.1-10.4) Urine only 3.7 (.04-10.2) 5.6 (0.7-15.7) Urine only 9.2 (3.0-18.8) 8.4 (1.7-20.3) Cervix/urine only 5.2 (1.9-10.1) 2.4 (0.3-6.7) Cervixurine only 4.3 (1.4-8.9) 3.6 (0.7-8.7) Any cervix/urine 17.4 (10.6-25.8) 14.6 (7.5-23.9) Any cervix/urine 10.4 (5.4-17.1) 9.7 (4.2-17.4) Any cervix/urine 27.8 (19.0-38.3) 24.2 (14.8-35.9) Any cervix/urine 0.9 (0.02-3.2) 1.2 (0.03-4.50 Any cervix/urine 0.9 (0.02-3.2) 1.2 (0.03-4.5) Anus only 5.9 (1.2-14.2) 2.7 (0.1-10.1) Any anus 47.1 (30.2-67.7) 44.0 (25.1-68.0) Any hands 28.2 (7.7-61.8) 16.1 (1.9-44.8) Self-inoculation Male ([section]) Penis only 4.9 (1.6-10.0) 2.4 (0.1-9.0) Scrotum only 6.0 (1.2-14.5) 7.5 (0.9-20.9) Any genital 13.6 (7.6-21.3) 11.7 (4.3-22.8) Any genital 2.7 (0.6-6.5) 3.9 (0.5-10.9) Anus only 10.2 (2.1-24.6) 9.3 (1.1-26.0) Female Cervix/urine only 0.9 (0.02-3.2) 1.2 (0.03-4.5) Cervix/urine/anus 1.8 (0.4-4.4) 1.7 (0.2-4.7) * HPV, human papillomavirus; CI, confidence interval. ([dagger]) Based on the duration of infection in the source site. When HPV was detected at a given visit followed by the absence of that HPV type at the successive visit, the exposure period was estimated at half of the visit interval. ([double dagger]) Includes probable oncogenic types. ([section]) Includes penis-to-penis subsite inoculations. Table 3. Characteristics of male-female couples by HPV transmission status * Transmission No transmission Characteristic (n = 16 couples) (n = 9 couples) Mean age (SD) M 25.4 (8.8) 32.2 (14.4) F 25.5 (10.2) 26.3 (7.3) Length of relationship, mo, median (range) 10.7 (1.9-73.4) 13.1 (0.23-185) Monthly frequency of sexual intercourse, mean (SD) 17.7 (10.0) 6.9 (7.8) Lifetime no. sexual partners, mean (SD) M 13.9 (10.4) 5.9 (5.1) F 6.7 (6.1) 2.8 (2.2) Circumcised man, no. (%) 13 (81) 7 (78) Sexual practices (ever/never), no. (%) Vaginal intercourse 32 (100) 18 (100) Anal intercourse 14 (44) 6 (33) Oral-vaginal 29 (91) 13 (72) Oral-penile 32 (100) 17 (94) Oral (M)--anal (F) 6 (19) 0 Oral (F)--anal (M) 2 (6) 0 (100) Finger/other object-vaginal 28 (88) 18 (22) Finger/other object (M)--anal (F) 9 (28) 4 (22) Finger/other object (F}--anal (M) 12 (38) 4 Contraception ever used with partner, no. (%) Birth control pill 21 (66) 8 (44) Birth control shot 6 (19) 0 "Morning after" pill 15 (16) 0 Spermicides 3 (9) 2 (11) Withdrawal 19 (59) 5 (28) Vasectomy 2 (6) 4 (22) Female condom 2 (6) 3 (17) Abstinence 5 (16) 8 (44) Condom 26 (81) 16 (89) Frequency of condom use (prior 4 mo), no. (%) Always 1 (3) 10 (56) Never/some use ([dagger]) 31 (97) 8 (44) Sexually transmitted infection history, no. (%) Chlamydia 4 (13) 0 Genital herpes 1 (3) 2 (11) Cigarette smoking (ever) ([double dagger]), no. (%) M 9 (56) 3 (33) F 4 (25) 0 Characteristic p value Mean age (SD) M 0.22 F 0.82 Length of relationship, mo, median (range) 0.22 Monthly frequency of sexual intercourse, mean (SD) 0.0002 Lifetime no. sexual partners, mean (SD) M 0.04 F 0.08 Circumcised man, no. (%) 0.84 Sexual practices (ever/never), no. (%) Vaginal intercourse 1.00 Anal intercourse 0.47 Oral-vaginal 0.09 Oral-penile 0.18 Oral (M)--anal (F) 0.05 Oral (F)--anal (M) 0.28 Finger/other object-vaginal 0.12 Finger/other object (M)--anal (F) 0.65 Finger/other object (F}--anal (M) 0.27 Contraception ever used with partner, no. (%) Birth control pill 0.15 Birth control shot 0.05 "Morning after" pill 0.08 Spermicides 0.84 Withdrawal 0.03 Vasectomy 0.10 Female condom 0.24 Abstinence 0.03 Condom 0.48 Frequency of condom use (prior 4 mo), no. (%) Always Never/some use ([dagger]) <0.0001 Sexually transmitted infection history, no. (%) Chlamydia 0.12 Genital herpes 0.25 Cigarette smoking (ever) ([double dagger]), no. (%) M 0.27 F 0.10 * HPV, human papillomavirus; SD, standard deviation. ([dagger]) Some use defined as usage less than half the time, half the time, or more than half the time. ([double dagger]) History of smoking daily for [greater than or equal to] 6 months.
|Printer friendly Cite/link Email Feedback|
|Author:||Hernandez, Brenda Y.; Wilkens, Lynne R.; Zhu, Xuemei; Thompson, Pamela; McDuffie, Katharine; Shvetso|
|Publication:||Emerging Infectious Diseases|
|Article Type:||Clinical report|
|Date:||Jun 1, 2008|
|Previous Article:||Managing potential laboratory exposure to Ebola virus by using a patient biocontainment care unit (1).|
|Next Article:||Population-attributable risk estimates for risk factors associated with Campylobacter infection, Australia.|